[1]
Segala, D., Barbieri, M., Di Nuzzo, M., Benazzi, M., Bonazza, A., Romanini, L., Quarta, B., Scolz, K., Marra, A., Campioni, D. and Cultrera, R. 2024. Clinical, organizational, and pharmacoeconomic perspectives of dalbavancin vs standard of care in the infectious disease network. Global and Regional Health Technology Assessment. 11, Suppl. 2 (Jul. 2024), 5–12. DOI:https://doi.org/10.33393/grhta.2024.3094.